NSD2 and plasma cell myeloma: Through this mechanism, SI‐2 disrupts the interaction between SRC‐3 and nuclear receptor binding SET domain protein 2 (NSD2), thereby enhancing the therapeutic sensitivity of multiple myeloma patients to bortezomib [62].